A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgestimate + ethinylestradiol in Italy.”

Imagine a new birth control pill is available, and doctors want to learn more about how it works for real women in everyday life. That's exactly what this study is doing for a pill called Effimia. It's designed to see how this specific birth control pill affects women's periods, whether they experience any unexpected bleeding or spotting, and how well they stick to taking it every day.

The main thing researchers are looking at is 'breakthrough bleeding'. This is when you have some bleeding or spotting in between your regular periods. They will specifically count how often this happens during the sixth month of using the pill. They'll compare this to how things were before the women started the pill. But it's not just about bleeding – they'll also be tracking other period details like how often they come, how long they last, and how heavy they are.

Beyond periods, the study will also check other important aspects of women's health. This includes looking at changes in acne, how mood is affected, and any impact on sexual function. They'll also measure period pain and keep track of how many women get pregnant while using the pill in the study. All of this information helps doctors understand the pill better and gives women clearer expectations.